Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...

The top model developers except one all have one thing in common: they are all currently founder-led companies. Alphabet is ...

Thank you for standing by, and welcome to Liftoff's Second Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jenn Kettnich, Head of Investor ...

Spread the loveWe stand at a fascinating crossroads in medicine, don’t we? The promise of Artificial Intelligence isn’t just ...

AI’s Next Breakthrough Could Be Biomedical Discovery / AI in healthcare, AI-innovation, artificial intelligence, Biomedical ...

In the rapidly evolving landscape of global market competition, optimizing the operational environment, establishing a ...

Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

A new study published in Nature Reviews Biodiversity by an international team of experts led by researchers from the ...

Prediction markets aren’t just a discussion of political races, they could be impacting the results — and in more ways than ...